Pliant Therapeutics, Inc. (PLRX)
| Market Cap | 79.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -175.50M |
| Shares Out | 61.45M |
| EPS (ttm) | -2.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 509,720 |
| Open | 1.270 |
| Previous Close | 1.290 |
| Day's Range | 1.270 - 1.325 |
| 52-Week Range | 1.090 - 3.460 |
| Beta | 1.35 |
| Analysts | Hold |
| Price Target | 3.75 (+188.46%) |
| Earnings Date | Mar 3, 2026 |
About PLRX
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibi... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PLRX stock is "Hold." The 12-month stock price target is $3.75, which is an increase of 188.46% from the latest price.
News
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration
Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional ba...
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-bas...
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatmen...
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based thera...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NE...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year S...
Pliant Therapeutics Provides Update on BEACON-IPF
Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June...
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical da...
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash r...
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 Ame...
Pliant Therapeutics: An Activist On Deck
Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value. Activist investor Kevin Tang has acquired a significant stake in PLRX...
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Antitumor activity observed with confirmed partial responses in 50% of patients at highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOU...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If ...
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockhol...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results
Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinica...
Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder
On Monday, Pliant Therapeutics Inc. PLRX announced that it would discontinue the BEACON-IPF Phase 2b trial, which evaluated bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial's ind...
The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Thera...
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / February 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / February 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co...
Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pliant Therapeutics, Inc. ("Pliant" or "the Co...